|
1
|
Hatzimichael E, Dasoula A, Benetatos L, et
al: Study of specific genetic and epigenetic variables in multiple
myeloma. Leuk Lymphoma. 51:2270–2274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rajumar SV and Greipp PR: Prognostic
factors in multiple myeloma. Hematol Oncol Clin North Am.
13:1295–1314. 1999. View Article : Google Scholar
|
|
3
|
Kyle RA and Rajkumar SV: Multiple myeloma.
N Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar
|
|
4
|
Klein U, Jauch A, Hielscher T, et al:
Chromosomal aberrations +1q21 and del(17p13) predict survival in
patients with recurrent multiple myeloma treated with lenalidomide
and dexamethasone. Cancer. 117:2136–2144. 2011.
|
|
5
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar
|
|
6
|
Jost E, Gezer D, Wilop S, et al:
Epigenetic dysregulation of secreted Frizzled-related proteins in
multiple myeloma. Cancer Lett. 281:24–31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boultwood J and Wainscoat JS: Gene
silencing by DNA methylation in haematological malignancies. Br J
Haematol. 138:3–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuregir OO, Yurtcu E, Kizilkilic E, Kocer
NE, Ozdogu H and Sahin FI: Detecting methylation patterns of p16,
MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int J
Lab Hematol. 32:142–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Braggio E, Maiolino A, Gouveia ME, et al:
Methylation status of nine tumor suppressor genes in multiple
myeloma. Int J Hematol. 91:87–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ullmannova-Benson V, Guan M, Zhou X, et
al: DLC1 tumor suppressor gene inhibits migration and invasion of
multiple myeloma cells through RhoA GTPase pathway. Leukemia.
23:383–390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Galm O, Yoshikawa H, Esteller M, Osieka R
and Herman JG: SOCS-1, a negative regulator of cytokine signaling,
is frequently silenced by methylation in multiple myeloma. Blood.
101:2784–2788. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Levy GG, Nichols WC, Lian EC, et al:
Mutations in a member of the ADAMTS gene family cause thrombotic
thrombocytopenic purpura. Nature. 413:488–494. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lo PH, Lung H, Cheung AK, et al:
Extracellular protease ADAMTS9 suppresses esophageal and
nasopharyngeal carcinoma tumor formation by inhibiting
angiogenesis. Cancer Res. 70:5567–5576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lung HL, Lo PH, Xie D, et al:
Characterization of a novel epigenetically-silenced,
growth-suppressive gene, ADAMTS9 and its association with lymph
node metastases in nasopharyngeal carcinoma. Int J Cancer.
123:401–408. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang C, Shao Y, Zhang W, et al:
High-resolution melting analysis of ADAMTS9 methylation levels in
gastric, colorectal and pancreatic cancers. Cancer Gene Cytogenet.
196:38–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuo HK, Griffith JD and Kreuzer KN:
5-Azacytidine induced methyltransferase-DNA adducts block DNA
replication in vivo. Cancer Res. 17:8248–8254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sidransky D: Emerging molecular markers of
cancer. Nat Rev Cancer. 2:210–219. 2002. View Article : Google Scholar
|
|
18
|
de Carvalho F, Colleoni GW, Almeida MS,
Carvalho AL and Vettore AL: TGFβR2 aberrant methylation is a
potential prognostic marker and therapeutic target in multiple
myeloma. Int J Cancer. 125:1985–1991. 2009.
|
|
19
|
Lo PH, Leung AC, Kwok CY, et al:
Identification of a tumor suppressive critical region mapping to
3p14.2 in esophageal squamous cell carcinoma and studies of a
candidate tumor suppressor gene, ADAMTS9. Oncogene. 26:148–157.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Zhang W, Shao Y, et al:
High-resolution melting analysis of ADAMTS18 methylation levels in
gastric, colorectal and pancreatic cancers. Med Oncol. 27:998–1004.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moncada-Pazos A, Obaya AJ, Fraga MF, et
al: The ADAMTS12 metalloprotease gene is epigenetically silenced in
tumor cells and transcriptionally activated in the stroma during
progression of colon cancer. J Cell Sci. 122:2906–2913. 2009.
View Article : Google Scholar
|
|
22
|
Viloria CG, Obaya AJ, Moncada-Pazos A, et
al: Genetic inactivation of ADAMTS15 metalloprotease in human
colorectal cancer. Cancer Res. 69:4926–4934. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dunn JR, Panutsopulo D, Shaw MW, et al:
METH-2 silencing and promoter hypermethylation in NSCLC. Br J
Cancer. 91:1149–1154. 2004.PubMed/NCBI
|
|
24
|
Dubail J, Kesteloot F, Deroanne C, et al:
ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule
independently of its catalytic activity. Cell Mol Life Sci.
67:4213–4232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
EI Hour M, Moncada-Pazos A, Blacher S, et
al: Higher sensitivity of Adamts12-deficient mice to tumor growth
and angiogenesis. Oncogene. 29:3025–3032. 2010.PubMed/NCBI
|
|
26
|
Dunn JR, Reed JE, du Plessis DG, et al:
Expression of ADAMTS-8, a secreted protease with antiangiogenic
properties, is downregulated in brain tumours. Br J Cancer.
94:1186–1193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koo BH, Coe DM, Dixon LJ, et al: ADAMTS9
is a cell-autonomously acting, anti-angiogenic metalloprotease
expressed by microvascular endothelial cells. Am J Pathol.
176:1494–1504. 2010. View Article : Google Scholar : PubMed/NCBI
|
